HE3286, a synthetic derivative of androst-5-ene-3β,7β,17β-triol (AET), a non-glucocorticoid anti-inflammatory metabolite of the adrenal steroid, dehydroepiandrosterone is under development by Harbor BioSciences as an anti-inflammatory; antiepileptic drugs; antihyperglycemic agent. HE3286 was studied in phase I clinical trials in Obese Adult Subjects, in Patients With Rheumatoid Arthritis in Patients With Active, Mild-to-Moderate Ulcerative Colitis, and in Patients With Type 2 Diabetes Mellitus. In all these studies were determined safety, tolerance, pharmacokinetics, and activity of HE3286. In addition, was shown that HE3286 acted via binding, regulation and/or activation of MAPK or ERK, or through modulation of NFκB. Experiments on animals have shown that the drug could have a neuroprotective influence in glaucoma, as well as other chronic neurodegenerations.